Top news of the day from across the health care landscape.
Early childhood diagnosis of type 1 diabetes could lead to a greater risk of heart disease and shorten life by as much as 18 years, Reuters reported. According to the article, a new study analyzed 27,195 individuals aged 18 years and older who had been diagnosed with type 1 diabetes and compared them with 135,178 age-matched people in the general population who did not have diabetes. Overall, individuals who developed type 1 diabetes before the age of 10 were more than 4 times as likely as their counterparts to die of any cause during the follow-up period, and 4 times as likely to die of cardiovascular disease.
On Thursday, the Trump administration proposed that US manufacturers cut production quotes of the 6 most abused opioids by 10% next year, Reuters reported. According to the article, the US Justice Department and Drug Enforcement Administration said they are proposing to cut production quotes for oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, and fentanyl by 7% to 15% in 2019. The agencies said in a statement that the proposed cut is in keeping with the president’s effort to cut opioid prescription fills by one-third within 3 years, the article reported.
Eisai Co Ltd announced it would price its new liver cancer drug Lenvima at nearly $16,000 for a 1-month supply before discounts, Reuters reported. The drug was approved by the FDA as the first therapy in more than a decade to treat previously untreated patients with unresectable hepatocellular carcinoma. According to the article, Lenvima is expected to bring in revenue of $3.46 billion by 2022.